Search results for "cetxuximab"

showing 1 items of 1 documents

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

2014

Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost–effectiveness involved with the use of the drug.

OncologySettore MED/06 - Oncologia MedicaCost effectivenessColorectal cancercost-effectiveneCetuximabColorectal NeoplasmPharmacologyAntineoplastic AgentPhosphatidylinositol 3-KinasesMutational statusMedicineNeoplasm MetastasiscetxuximabProto-Oncogene ProteinTOR Serine-Threonine KinaseCetuximabPharmacogeneticTOR Serine-Threonine KinasesNeoplasm MetastasiErbB ReceptorsMolecular MedicineColorectal NeoplasmsHumanmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtypharmacogenomicEGFRAntineoplastic AgentsAntibodies Monoclonal HumanizedresistanceProto-Oncogene Proteins p21(ras)Geneticcolorectal carcinomaProto-Oncogene ProteinsInternal medicineGeneticsHumanspredictivecost-effectivenessneoplasmspharmacogenomicsPharmacologybusiness.industryPTEN Phosphohydrolaseras Proteinmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmPharmacogeneticsPharmacogenomicsMutationras ProteinsReceptor Epidermal Growth FactorPhosphatidylinositol 3-KinasebusinessProto-Oncogene Proteins c-aktPharmacogeneticsRASPharmacogenomics
researchProduct